Goodman Advisory Group, LLC Gilead Sciences, Inc. Transaction History

Goodman Advisory Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $699,408 - $852,910	-9,771 Reduced 12.54%	68,144 $4.99 Million
Q4 2023 Jan 30, 2024	SELL	$73.27 - $83.09 $1.31 Million - $1.48 Million	-17,821 Reduced 18.61%	77,915 $6.31 Million
Q3 2023 Oct 11, 2023	SELL	$73.94 - $80.67 $709,750 - $774,351	-9,599 Reduced 9.11%	95,736 $7.17 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $265,730 - $303,103	-3,496 Reduced 3.21%	105,335 $8.12 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $3.57 Million - $4.07 Million	46,240 Added 73.88%	108,831 $9.03 Million
Q4 2022 Jan 20, 2023	BUY	$62.32 - $89.47 $328,239 - $471,238	5,267 Added 9.19%	62,591 $5.37 Million
Q3 2022 Oct 17, 2022	BUY	$59.54 - $68.01 $2.17 Million - $2.47 Million	36,382 Added 173.73%	57,324 $3.54 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $1.21 Million - $1.36 Million	20,942 New	20,942 $1.29 Million

1,879

1.02B

12M

8.96M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Goodman Advisory Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Goodman Advisory Group, LLC with notifications on news.